Meeting
2021 ASCO Annual Meeting
Outcomes of ovarian cancer patients treated with platinum or non-platinum based chemotherapy after PARP inhibitor maintenance.
Authors
Ralynn Brann
The University of Texas Southwestern Medical Center, Dallas, TX
Ralynn Brann , Kevin Michael Kremer , Matthew Carlson , Salvatore LoCoco , Jayanthi Sivasothy Lea , David Scott Miller , Jessica Lee
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 5563)
DOI
10.1200/JCO.2021.39.15_suppl.5563
Abstract #
5563
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Oregovomab and non-platinum chemotherapy in PARP inhibitor-resistant ovarian, fallopian tube, or primary peritoneal cancer patients not candidates for platinum retreatment: A multicenter, two-cohort, single-arm phase 2 trial (OPERA/KGOG 3065/APGOT-OV6).
First Author: JUNG-YUN LEE
Poster
2022 ASCO Annual Meeting
A descriptive study on the treatment and outcomes of patients with platinum-sensitive, advanced, BRCA- or PALB2-related pancreatic cancer who have progressed on rucaparib.
First Author: Timothy J Brown
Poster
2020 ASCO Virtual Scientific Program
Concordance between CA-125 and RECIST progression (PD) in patients with germline BRCA-mutated platinum-sensitive, relapsed ovarian cancer treated with a PARP inhibitor (PARPi) as maintenance therapy after response to chemotherapy.
First Author: Angelina Tjokrowidjaja
Poster
2020 ASCO Virtual Scientific Program
NOGGO Ov-42/MAMOC: Rucaparib maintenance after bevacizumab maintenance following carboplatin-based first line-chemotherapy in ovarian cancer patients.
First Author: Elena Ioana Braicu